|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N03AX23
|
|
gptkbp:brand
|
gptkb:Briviact
|
|
gptkbp:CASNumber
|
357336-20-0
|
|
gptkbp:category
|
antiepileptic drug
central nervous system agent
|
|
gptkbp:chemicalClass
|
racetam
|
|
gptkbp:contraindication
|
hypersensitivity to brivaracetam
|
|
gptkbp:developedBy
|
gptkb:UCB_Pharma
|
|
gptkbp:eliminationHalfLife
|
7-8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
2004
|
|
gptkbp:form
|
gptkb:tablet
oral solution
injectable solution
|
|
gptkbp:hasInChIKey
|
QXWZOBLZJGMJDC-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C11H20N2O2
|
|
gptkbp:hasSMILES
|
CC(C)C(=O)N1CCC(CC1)NC(=O)C2CC2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brivaracetam
|
|
gptkbp:KEGGID
|
D10541
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
selective synaptic vesicle protein 2A (SV2A) ligand
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:patent
|
gptkb:UCB_Pharma
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
<20%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105757
8013338
9837247
DB06220
|
|
gptkbp:relatedTo
|
gptkb:Levetiracetam
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
nausea
anxiety
dizziness
fatigue
irritability
somnolence
|
|
gptkbp:synonym
|
gptkb:UCB-34714
|
|
gptkbp:UNII
|
6H8N5P8K0E
|
|
gptkbp:usedFor
|
epilepsy
partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:N03AX16
|
|
gptkbp:bfsLayer
|
6
|